<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559217</url>
  </required_header>
  <id_info>
    <org_study_id>2021-3828</org_study_id>
    <nct_id>NCT04559217</nct_id>
  </id_info>
  <brief_title>68Ga-DOTATATE Neuroblastoma Imaging Pilot</brief_title>
  <official_title>Pilot Study of 68Ga-DOTATATE PET/CT and 123I-MIBG Scintigraphy Imaging of Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of&#xD;
      approximately 10.2 per million children. Staging of the disease can be done by different&#xD;
      imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among&#xD;
      these different strategies resulting in different treatment strategies. The goal of this&#xD;
      study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG&#xD;
      when investigating neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Neuroblastoma is the most frequent extracranial childhood tumor, with an annual&#xD;
      incidence of approximately 10.2 per million children. Initial staging of the disease and&#xD;
      monitoring of the treatment response can be performed with different imaging modalities that&#xD;
      include contrast-enhanced computed tomography (ceCT), ultrasound, magnetic resonance imaging&#xD;
      (MRI), bone scintigraphy and 123I-MIBG scintigraphy.&#xD;
&#xD;
      Another potential target for neuroblastoma imaging is the somatostatin receptor (SSTR) that&#xD;
      is present in many neuroendocrine tumours (NET). The superior PET imaging technology used&#xD;
      with new radiotracers (such as 68Ga-DOTATATE) enables imaging at advantageous resolutions&#xD;
      well below what is possible by current clinical SPECT systems that are used for 123I-MIBG.&#xD;
&#xD;
      Design: Prospective single-arm non-randomized clinical trial (phase II) - pilot&#xD;
&#xD;
      Objective: 1) Assess the feasibility and safety of 68Ga-DOTATATE PET/CT imaging in patients&#xD;
      with neuroblastoma or suspected of having neuroblastoma. 2) Compare lesion-by-lesion the&#xD;
      uptake of 68Ga-DOTATATE and 123I-MIBG in the same participant.&#xD;
&#xD;
      Study population: Children and adults with biopsy-proven or suspected neuroblastoma&#xD;
&#xD;
      Procedure and Follow-up: Few days after 123I-MIBG scan, participants will undergo a&#xD;
      68Ga-DOTA-cTATE PET/CT scan (duration 2 hours). Clinical data will be collected from this&#xD;
      imaging and from the participant's medical record (demographic, treatment, medication,&#xD;
      pathology, lab test results) for a 2-year follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective pilot study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accrual rate</measure>
    <time_frame>For the duration of the study, lasting 6 years</time_frame>
    <description>Number of participants enrolled / year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>Up to 24 hours following injection of 68Ga-DOTATATE</time_frame>
    <description>Number of adverse events (being serious or not) associated to the intervention (injection of 68Ga-DOTATATE and PET/CT acquisition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive lesions for 68Ga-DOTATATE</measure>
    <time_frame>One hour post-injection of 68Ga-DOTATATE</time_frame>
    <description>SUV mean of the lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discordance of positive lesions for 68Ga-DOTATATE and positive lesions of 123I-MIBG</measure>
    <time_frame>Within one week (period between 123I-MIBG scan and 68Ga-DOTATATE scan)</time_frame>
    <description>the number of discordant lesions divided by the number of total positive lesions is the discordance rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Single arm with 68Ga-DOTATATE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all participants will undergo a PET scan with 68Ga-DOTATATE</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Radiopharmaceutical 68Ga-DOTATATE</intervention_name>
    <description>Injection of 68Ga-DOTATATE followed by PET/CT acquisition</description>
    <arm_group_label>Single arm with 68Ga-DOTATATE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma&#xD;
&#xD;
          -  Planned 123I-MIBG imaging&#xD;
&#xD;
          -  Able and willing to provide signed informed consent in French or English (for the&#xD;
             adult candidates or the parent/legal tutor of the pediatric candidates)&#xD;
&#xD;
          -  Aged between 1 day and 21 years old (inclusively).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another cancer in the past 5 years other than non-melanomatous skin cancer.&#xD;
&#xD;
          -  Currently under a randomized control trial with unknown allocation;&#xD;
&#xD;
          -  Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT&#xD;
             scan.&#xD;
&#xD;
          -  Medically unstable or unable to undergo scan.&#xD;
&#xD;
          -  Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at&#xD;
             least 12 hours after 68Ga-DOTATATE injection).&#xD;
&#xD;
          -  Prior allergic reaction to somatostatin analogues&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Etienne Rousseau, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIUSSSE-CHUS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amelie Tetu, MSc</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>15571</phone_ext>
    <email>amelie.tetu.ciussse-chus@ssss.gouv.qc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Pier Houde, MSc</last_name>
    <phone>819-346-1110</phone>
    <phone_ext>12804</phone_ext>
    <email>marie-pier.houde.ciussse-chus@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIUSSS de L'Estrie-CHUS Hospital</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Etienne Croteau, PhD</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>11894</phone_ext>
      <email>etienne.croteau.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Amelie Tetu, MSc</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>15571</phone_ext>
      <email>amelie.tetu.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Etienne Rousseau, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>imaging</keyword>
  <keyword>68Ga-Dotatate</keyword>
  <keyword>68Ga-Octreotate</keyword>
  <keyword>positron emission tomography (PET)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiopharmaceuticals</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

